Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56

Benzinga Newsdesk www.benzinga.com Positive 76.6%

Neg 0% Neu 0% Pos 76.6%

Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.